Proton pump inhibitors, medications that suppress acid in the stomach, appear to be associated with fractures in postmenopausal women and bacterial infections in many patients, and higher doses do not appear any more beneficial for treating bleeding ulcers.
A series of these reports are published in the May 10 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
An additional report finds that introducing guidelines for proton pump inhibitor use into clinical settings may reduce rates of inappropriate prescriptions.
“A staggering 113.4 million prescriptions for proton pump inhibitors are filled each year, making this class of drugs, at $13.9 billion in sales, the third highest seller in the United States,” writes Mitchell H. Katz, M.D., of the San Francisco Department of Public Health. These medications effectively treat inflammation of the esophagus, gastroesophageal reflux disease (GERD), ulcers and several other conditions, but evidence suggests that between 53 percent and 69 percent of proton pump inhibitor prescriptions are for inappropriate indications, he notes.
“All drugs have adverse effects, but that alone is not a reason to avoid them. Rather, prior to prescribing medications, good clinicians must weigh the benefits vs. the risks and the seriousness of the disease vs. the seriousness of the adverse effects,” Dr. Katz writes. Proton pump inhibitors are often used to treat dyspepsia, or indigestion, in the absence of ulcers, inflammation or severe GERD. “That proton pump inhibitors relieve dyspepsia is without question, but at what cost (and I do not mean financial)? Five studies in this issue of the Archives help to answer this question.”
The studies find that:
? Use of proton pump inhibitors appears modestly associated with the risk of total fractures in postmenopausal women.
? Daily proton pump inhibitor use is associated with an estimated 74 percent increase in infection with Clostridium difficile.
? High-dose proton pump inhibitors do not appear to be associated with reduced rates of additional bleeding, surgical intervention or death in patients with bleeding ulcers when compared with regular proton pump inhibitor therapy.
? Implementing standardized guidelines based on medical evidence appeared to be associated with reductions in prescriptions for proton pump inhibitors at one facility.
“Harm will result if these commonly used medications are prescribed for conditions for which there is no benefit, such as non-ulcer dyspepsia,” write Deborah Grady, M.D., M.P.H., of University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, and Rita F. Redberg, M.D., M.Sc., also of University of California, San Francisco, and editor of the Archives, in another editorial.
Source: Archives of Internal Medicine, USA